NASDAQ:BDSIBioDelivery Sciences International Stock Price, Forecast & News

BioDelivery Sciences International's stock was trading at $3.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BDSI shares have increased by 13.9% and is now trading at $4.51. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioDelivery Sciences International in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BioDelivery Sciences International.

BioDelivery Sciences International is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for BioDelivery Sciences International.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) issued its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $0.05 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.01 by $0.04. The specialty pharmaceutical company earned $38.28 million during the quarter, compared to analysts' expectations of $33.19 million. BioDelivery Sciences International had a positive return on equity of 23.61% and a negative net margin of 5.01%. View BioDelivery Sciences International's earnings history.

8 brokers have issued 12-month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $8.00 to $9.25. On average, they anticipate BioDelivery Sciences International's stock price to reach $8.71 in the next year. This suggests a possible upside of 93.1% from the stock's current price. View analysts' price targets for BioDelivery Sciences International.

Headlines about BDSI stock have trended negative recently, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioDelivery Sciences International earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about BioDelivery Sciences International.

Some companies that are related to BioDelivery Sciences International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioDelivery Sciences International investors own include TG Therapeutics (TGTX), Eldorado Gold (EGO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Baidu (BIDU), JD.Com (JD), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

BioDelivery Sciences International's stock is owned by a variety of institutional and retail investors. Top institutional investors include Canandaigua National Corp (0.01%) and Diversified Trust Co (0.01%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, James Vollins, Mark A Sirgo, Mary Theresa Coelho, Paolantonio Ernest Robert De, Scott M Plesha and Thomas B Smith. View institutional ownership trends for BioDelivery Sciences International.

BDSI stock was acquired by a variety of institutional investors in the last quarter, including Canandaigua National Corp, and Diversified Trust Co. View insider buying and selling activity for BioDelivery Sciences International.

Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BDSI stock can currently be purchased for approximately $4.51.

BioDelivery Sciences International has a market capitalization of $451.74 million and generates $111.39 million in revenue each year. The specialty pharmaceutical company earns $-15,310,000.00 in net income (profit) each year or $0.10 on an earnings per share basis. BioDelivery Sciences International employs 178 workers across the globe.

The official website for BioDelivery Sciences International is www.bdsi.com.

BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]